Skip to content

Zachary Herrmann

3 papers in the library · 33 citations · publishing 2022-2023

Papers

Sort Most recent Most cited

Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.

Psychedelic medicine (New Rochelle, N.Y.) September 1, 2023 Zachary Herrmann, Adam W. Levin, Steven P Cole et al. 9 citations

Mental health problems including depression, anxiety, suicide, and burnout are common among health care providers. Resilience and well-being are factors thought to protect against these incidents. Clinical trials and naturalistic studies of psychedelic compounds have shown decreases in depression, anxiety, and suicidality while suggesting improvements in well-being. This secondary analysis of a...

Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials.

Journal of Psychoactive Drugs 2023 Zachary Herrmann, Mitch Earleywine, Joseph A. de Leo et al. 19 citations

Subjective responses to psychoactive drugs have served as intriguing windows into consciousness as well as useful predictors. Subjective reactions to psychedelic molecules are particularly interesting given how they covary with subsequent improvements associated with psychedelic-assisted treatments. Although links between subjective reactions and decreases in treatment-resistant clinical...

Psychedelics for Psychiatric Disorders: Promise, Not Panacea

Psychiatric Annals September 1, 2022 Mitch Earleywine, Zachary Herrmann 5 citations

Initial promise and dire need have inspired the multiple research programs of the second psychedelic renaissance. Serotonergic psychedelics (psilocybin, lysergic acid diethylamide, and ayahuasca) have decreased end-of-life anxiety in cancer patients, treatment-resistant depression, alcohol dependence, social anxiety in autistic adults, and nicotine dependence when applied with supportive...